Ipamorelin Dosage Protocol Guide 2026: Reconstitution, Timing & Research Use

# Ipamorelin Dosage Protocol Guide 2026: Reconstitution, Timing & Research Use

> ⚠️ Research Use Only: Ipamorelin is an investigational research peptide not approved by the FDA for human use. This article is for educational and scientific research purposes only. All dosage information refers to protocols reported in peer-reviewed literature and preclinical or clinical research studies. Nothing in this guide constitutes medical advice, a clinical recommendation, or an endorsement of self-experimentation.

What Is Ipamorelin?

Ipamorelin (NNC 26-0161) is a synthetic pentapeptide growth hormone secretagogue (GHS) that selectively stimulates growth hormone (GH) release from the anterior pituitary via agonism of the growth hormone secretagogue receptor 1a (GHS-R1a). It was developed by Novo Nordisk in the 1990s and has been extensively studied in both rodent models and early-phase human trials.

What distinguishes ipamorelin from earlier-generation GHRPs such as GHRP-2 and GHRP-6 is its receptor selectivity. At research-relevant doses, ipamorelin produces robust GH pulses without meaningfully elevating cortisol, ACTH, or prolactin — hormones that earlier GHRPs elevated substantially. This cleaner hormonal profile makes ipamorelin particularly useful as a pharmacological tool for studying isolated GH axis activity.

For a comprehensive mechanistic overview including pharmacokinetics, receptor binding data, and preclinical study results, see the complete Ipamorelin research profile.

---

Literature-Reported Research Dosages

Dose-Response Characteristics

The pharmacology literature establishes that ipamorelin exhibits a saturation dose at the level of pituitary GHS-R1a receptor occupancy. Published research consistently identifies this saturation point at approximately 100 mcg per injection — meaning that beyond this threshold, additional peptide does not proportionally increase peak GH amplitude because receptor occupancy is approaching maximum.

Key dose-response parameters from the research literature:

A Phase II trial by Svensson et al. (1998) demonstrated dose-dependent GH release in human subjects across subcutaneous doses of 1–100 mcg/kg, with a plateau in peak GH response observed at the upper end of the range. This saturation kinetic is a foundational finding that underlies most subsequent ipamorelin research protocol designs.

Standard Research Protocol Dosing

Based on published and reported research protocols, ipamorelin doses in research studies cluster in a consistent range:

• •Low-dose protocols: 100 mcg per injection, 1–2× daily
• •Standard protocols: 100–200 mcg per injection, 2–3× daily
• •High-frequency protocols: 100–300 mcg per injection, 3× daily (morning, pre-exercise, pre-sleep)

The 100 mcg threshold is frequently used as the reference dose in comparative studies precisely because it reliably produces near-maximal GH pulse amplitude while remaining below the range where off-target receptor interactions might confound the research.

---

Reconstitution Protocol

Ipamorelin is commercially supplied as a lyophilized (freeze-dried) white powder in sterile, sealed vials. Standard vial sizes in the research market are 2 mg, 5 mg, and 10 mg.

Required Materials

• •Ipamorelin lyophilized powder vial
• •Bacteriostatic water (BAC water — 0.9% benzyl alcohol in sterile water)
• •Sterile insulin syringes (U-100, typically 28–30G needles)
• •Alcohol swabs

Why Bacteriostatic Water

Bacteriostatic water (BAC water) is the standard reconstitution solvent for research peptides intended for multi-dose use. The 0.9% benzyl alcohol acts as a preservative between needle accesses, extending the stability window of the reconstituted solution to approximately 28 days at 2–8°C. Standard sterile water without a preservative should be used within 72 hours and is impractical for multi-dose research protocols.

Concentration Calculation

Choosing your diluent volume determines the resulting concentration and thus the injection volume per dose:

The 1,000 mcg/mL (1 mg/mL) concentration is widely used in research settings because it produces a convenient, measurable injection volume per dose. For a standard 100 mcg injection at this concentration, the researcher draws exactly 10 units on a U-100 insulin syringe.

Step-by-Step Reconstitution

1. Allow the lyophilized vial to reach room temperature before opening (reduces condensation risk)

2. Wipe both the peptide vial septum and the BAC water vial septum with alcohol swabs; allow to dry

3. Draw the desired volume of BAC water into a sterile syringe

4. Insert the needle through the peptide vial septum at an angle, directing the BAC water slowly down the inner glass wall — never inject directly onto the lyophilized cake, as this can cause aggregation and peptide degradation

5. Gently swirl the vial — do not shake, as mechanical agitation can disrupt peptide structure

6. Allow to dissolve fully (typically 30–60 seconds); the solution should be clear and colorless

7. Label the vial with reconstitution date and final concentration

---

Administration Timing in Research Protocols

Physiological Basis for Timing

Ipamorelin's efficacy in stimulating GH pulses is substantially influenced by baseline somatostatin tone. Somatostatin is the hypothalamic hormone that inhibits GH release; elevated somatostatin suppresses the GH response to GHS-R1a agonists. Two physiological states reliably reduce somatostatin tone and therefore maximize the GH-stimulatory response to ipamorelin:

1. Fasted state — postprandial insulin elevation suppresses somatostatin clearance; the fasted state allows somatostatin levels to fall

2. Early sleep onset — endogenous GH secretion is highest in the first hours of deep sleep; this pulsatile release occurs in a low-somatostatin window

Common Timing Protocols in the Literature

Pre-sleep administration is the most consistently reported timing approach in human-model ipamorelin research. Administration 30–60 minutes before sleep exploits the natural low-somatostatin window of early sleep and may augment the endogenous nocturnal GH pulse. Studies examining slow-wave sleep GH secretion typically use this timing.

Fasted morning administration takes advantage of the lowest daily somatostatin tone, which occurs after the overnight fast. Some protocols pair morning administration with an additional post-sleep fast of 30–60 minutes before the injection to maximize the window.

Pre-exercise administration (30–60 minutes before resistance training) is used in studies examining the interaction between exercise-stimulated GH release and pharmacological GHS-R1a agonism. Exercise alone stimulates GH release through partially overlapping mechanisms, and pre-exercise ipamorelin administration has been studied for additive or synergistic GH pulse effects.

Multi-injection protocols distribute injections across the day to maximize cumulative GH exposure across the circadian cycle:

All administrations in literature protocols consistently maintain a minimum 2-hour fast before the injection. Food consumption — particularly carbohydrates — elevates insulin and blunts somatostatin clearance, reducing the GH response to ipamorelin by as much as 50% in some reported pharmacodynamic data.

---

Ipamorelin vs. GHRP-6 Dosing Differences

Ipamorelin and GHRP-6 share a common receptor (GHS-R1a) but produce meaningfully different pharmacological profiles that affect how researchers design protocols with each compound.

Dose Saturation

Both peptides exhibit GH response saturation, but the clinical threshold and off-target activity profiles differ:

Protocol Design Implications

Because GHRP-6 elevates cortisol and ACTH in a dose-dependent manner, protocols using GHRP-6 must account for HPA axis confounding when studying body composition, metabolic function, or stress responses. Ipamorelin's selectivity makes it a cleaner tool for studying isolated GH effects.

GHRP-6's appetite stimulation (mediated by hypothalamic ghrelin receptor pathways) is sometimes deliberately exploited in cachexia and appetite research — a use case where ipamorelin is not the preferred compound due to its lack of this effect.

For research purposes where GH axis study is the primary objective and HPA axis confounding must be minimized, ipamorelin is generally preferred over GHRP-6. For research purposes where appetite stimulation is a studied variable, GHRP-6 is the more appropriate tool.

For a detailed head-to-head analysis, see Ipamorelin vs GHRP-6: Research Comparison Guide.

---

Combination Protocols in Research: Ipamorelin + CJC-1295

The most extensively documented combination protocol in the GHRP literature pairs ipamorelin with CJC-1295 (a growth hormone-releasing hormone analog). These two compounds act through entirely different receptor systems:

• •Ipamorelin → GHS-R1a (ghrelin receptor pathway; calcium/PLC second messenger)
• •CJC-1295 → GHRH-R (GHRH receptor; cAMP/PKA second messenger)

Because these receptor systems are independent and downstream of each other in the GH secretion cascade, their effects on GH vesicle exocytosis are additive at minimum, and the published literature frequently characterizes combined administration as producing a synergistic GH pulse — larger than either compound alone at equivalent individual doses.

Reported Combination Dosing

Research protocols pairing CJC-1295 (no DAC) with ipamorelin consistently report:

• •Ipamorelin: 100–200 mcg per injection
• •CJC-1295 (no DAC): 100–200 mcg per injection
• •Administration: Simultaneously (co-injection or sequential within a 5-minute window)
• •Frequency: 1–3× daily, with pre-sleep timing as the primary anchor injection

CJC-1295 with DAC (drug affinity complex) uses a fundamentally different pharmacokinetic approach — extended half-life via albumin binding produces sustained GHRH-R stimulation rather than pulsatile stimulation. DAC formulations are typically dosed weekly rather than daily and produce a different (tonic rather than pulsatile) GH release pattern. Most research protocols studying pulsatile GH secretion use CJC-1295 without DAC.

For the complete stack protocol analysis including triple-stack extension with MK-677, see the CJC-1295 + Ipamorelin Stack Research Guide.

---

Storage and Stability

Lyophilized (Pre-Reconstitution)

Protect lyophilized vials from light and humidity. Do not store in frost-free freezers that cycle temperatures, as repeated freeze-thaw cycles degrade the peptide.

Reconstituted Solution

Reconstituted ipamorelin solutions should be kept in the refrigerator and not frozen. Use BAC water for multi-dose vials; if using sterile water (no bacteriostatic agent), use within 72 hours.

Identifying Degradation

A properly reconstituted ipamorelin solution is clear and colorless. Discard the vial if the solution appears:

• •Cloudy or turbid
• •Discolored (yellow, brown)
• •Contains visible particulates that do not dissolve after gentle swirling

---

Ipamorelin Supplier Price Comparison

Research-grade ipamorelin is widely available from verified suppliers on peptides.so. Current listing data shows significant price variation across suppliers, primarily driven by vial size and purity specification:

For a real-time comparison of all suppliers, verified availability, and COA (certificate of analysis) links, use the Ipamorelin price comparison tool.

When evaluating suppliers, researchers should prioritize:

• •Third-party HPLC/MS testing with published COA documents
• •Sterility testing for injectable-grade research peptides
• •Clear labeling of purity percentage and lot-specific certificates

---

Key Research Protocol Parameters: Summary Table

---

Frequently Asked Questions

Can ipamorelin be combined with other peptides in research?

Yes — the most common combination in the literature pairs ipamorelin with a GHRH analog (CJC-1295 without DAC) to amplify GH pulse magnitude through dual-receptor stimulation. Some protocols extend this with MK-677 (ibutamoren), an oral ghrelin mimetic that sustains elevated GH/IGF-1 between injection windows.

Why does the pre-injection fast matter?

Insulin elevation from food intake indirectly maintains somatostatin tone. Since somatostatin antagonizes GH release and competes with GHS-R1a-mediated stimulation, a fed state substantially blunts the GH response to ipamorelin. Multiple pharmacodynamic studies document this interaction.

What distinguishes ipamorelin from earlier GHRPs in research applications?

The key distinguishing feature is receptor selectivity. Ipamorelin produces GH release without meaningfully elevating cortisol, ACTH, or prolactin at research-relevant doses. This makes it a cleaner experimental tool when the objective is studying isolated GH axis effects, without the confounding neuroendocrine effects associated with GHRP-2 and GHRP-6.

Is GHRP-6 or ipamorelin preferred in research?

The choice depends on the research question. For isolated GH axis study, ipamorelin is generally preferred. For appetite/ghrelin pathway research, GHRP-6's stronger orexigenic effects may be the feature under study. See the full comparison guide for a detailed breakdown.

---

Disclaimer

> ⚠️ Research Use Only: Ipamorelin is an investigational research peptide not approved by the U.S. Food and Drug Administration (FDA) or equivalent regulatory bodies for human therapeutic use. All information presented in this article is sourced from peer-reviewed scientific literature, preclinical research data, and early-phase clinical pharmacology studies. This content is provided for educational and scientific research purposes only.

>

> This article does not constitute medical advice, clinical guidance, or a recommendation for human use. Researchers must comply with all applicable institutional, regulatory, and legal requirements governing the use of investigational compounds. Do not use this information for self-experimentation or human administration outside of an approved clinical research framework.